keyword
MENU ▼
Read by QxMD icon Read
search

Second primary, lung cancer

keyword
https://www.readbyqxmd.com/read/29019334/brain-metastasis-from-colorectal-adenocarcinoma-a-case-report
#1
Jaroslav Nemec, Abdulsalam Alnajjar, Jasem Albarrak, Shaban A, Mariam Al Otaibi, Asit Mohanty
Colorectal cancer (CRC) is the third leading cause of cancer death in the Western world, accounting for approximately 140,000 new cases and more than 51,000 deaths in 2010 in the United States. In Kuwait, CRC is the first most-diagnosed neoplasm among males and overall, the second leading cause of death from cancer. The 5-year survival rate in 2002-2004 was 61% for men and 62% for women. Even after complete resection of the colorectal tumor, distant metastases have been noted to develop in 10%-15% of patients...
September 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/29019328/second-primary-tumors-associated-with-breast-cancer-kuwait-cancer-control-center-experience
#2
Salah Fayaz, Gerges Attia Demian, Heba El-Sayed Eissa, Sadeq Abuzalouf
OBJECTIVES: To review the clinico-epidemiologic characteristics of patients who presented with two or more primary cancers, one of which was breast cancer (BC) and to develop a follow-up program for the high risk patients. PATIENTS AND METHODS: Patients who were diagnosed with BC and one or more non breast cancer (NBC) were retrospectively reviewed. Medical files were retrieved and epidemiological as well as clinical data were analyzed. RESULTS: Sixty-two patients were retrieved...
September 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/29018502/persistent-tracheostomy-after-organ-preservation-protocol-in-patients-treated-for-larynx-and-hypopharynx-cancer
#3
Carlos Miguel Chiesa Estomba, Frank Alberto Betances Reinoso, Virginia Martinez Villasmil, Maria Jesus González Cortés, Carmelo Santidrian Hidalgo
Introduction  Squamous cell carcinoma of the larynx is currently the second most common malignancy of the airway after lung cancer, and hypopharyngeal cancer accounts for fewer than 5% of head and neck cancers. The nonsurgical options for patients with this disease are related to significant long-term toxicities and the need for persistent tracheostomy, which adversely affects the quality of life of these patients. Objective  To evaluate the need for tracheostomy, and the influence of this in the overall and specific survival rates of patients diagnosed with all stages of laryngeal carcinoma treated by chemoradiotherapy...
October 2017: International Archives of Otorhinolaryngology
https://www.readbyqxmd.com/read/28989038/risk-of-second-lung-cancer-in-patients-with-previously-treated-lung-cancer-analysis-of-surveillance-epidemiology-and-end-results-seer-data
#4
Manish K Thakur, Julie J Ruterbusch, Ann G Schwartz, Shirish M Gadgeel, Jennifer L Beebe-Dimmer, Antoinette J Wozniak
BACKGROUND: The risk of developing a second primary lung cancer (SPLC) after the treatment of an initial primary lung cancer (IPLC) is around 1-2 % per patient per year. Present screening/surveillance guidelines do not adequately address this particular patient population. PATIENTS AND METHODS: We retrospectively reviewed patients in the Surveillance, Epidemiology, and End Results (SEER) data base from 1992 to 2007 to assess the frequency of occurrence of SPLC with regard to multiple patient demographics and calculated Standardized Incidence Ratios (SIRs)...
October 5, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28983776/second-primary-cancer-after-liver-transplantation-in-hepatocellular-carcinoma-a-nationwide-population-based-study
#5
Jaesung Heo, O Kyu Noh, Young-Taek Oh, Mison Chun, Logyoung Kim
PURPOSE: The aim of this study is to evaluate prevalence of second primary cancer (SPC) among hepatocellular carcinoma (HCC) patients after liver transplantation (LT) by using nationwide claims data from South Korea. MATERIALS AND METHODS: The nationwide cohort included patients who were diagnosed with HCC and received LT from 1 January 2010 to 31 December 2014. We analyzed frequency and standardized incidence ratios (SIRs) to estimate the risk of SPC in HCC patients after LT...
October 5, 2017: Hepatology International
https://www.readbyqxmd.com/read/28978922/therapeutic-pcl-scaffold-for-reparation-of-resected-osteosarcoma-defect
#6
Ilaria E Palamà, Valentina Arcadio, Stefania D'Amone, Mariano Biasiucci, Giuseppe Gigli, Barbara Cortese
Osteosarcomas are highly malignant tumors, which develop rapid growth and local infiltration, inducing metastases that spread primarily in the lung. Treatment of these tumors is mainly based on pre- and post-operative chemotherapy and surgery of the primary tumor. Surgical resection though, generates bone defects. Reparation of these weaknesses presents formidable challenges to orthopedic surgery. Medicine regenerative grafts that act as both tumor therapy with constant local drug delivery and tissue regeneration may provide a new prospect to address this need...
October 4, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28975219/association-of-immune-related-adverse-events-with-nivolumab-efficacy-in-non-small-cell-lung-cancer
#7
Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, Keita Kudo, Kimio Yonesaka, Ryoji Kato, Hiroyasu Kaneda, Yoshikazu Hasegawa, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawa
Importance: Immune-related adverse events (irAEs) have been associated with the efficacy of PD-1 (programmed cell death protein 1) inhibitors in patients with melanoma, but whether such an association exists for non-small-cell lung cancer (NSCLC) has remained unknown. Objective: To evaluate the relation of irAEs to nivolumab efficacy in NSCLC. Design, Setting, and Participants: In this study based on landmark and multivariable analyses, a total of 134 patients with advanced or recurrent NSCLC who were treated with nivolumab in the second-line setting or later between December 2015 and August 2016 were identified from a review of medical records from multiple institutions, including a university hospital and community hospitals...
September 21, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28963651/lung-injury-and-expression-of-p53-and-p16-in-wistar-rats-induced-by-respirable-chrysotile-fiber-dust-from-four-primary-areas-of-china
#8
Yali Zeng, Yan Cui, Ji Ma, Tingting Huo, Faqin Dong, Qingbi Zhang, Jianjun Deng, Xu Zhang, Jie Yang, Yulin Wang
Chrysotile products were widely used in daily life, and a large amount of respirable dust was produced in the process of production and application. At present, there was seldom research on the safety of chrysotile fiber dust, and whether its long-term inhalation can lead to lung cancer was unknown. In order to determine whether respirable chrysotile fiber dust of China caused lung cancer, four major chrysotile-producing mine areas in China were selected for this study. Chrysotile fibers were prepared into respirable dust...
September 29, 2017: Environmental Science and Pollution Research International
https://www.readbyqxmd.com/read/28958502/dacomitinib-versus-gefitinib-as-first-line-treatment-for-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-archer-1050-a-randomised-open-label-phase-3-trial
#9
Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, Rolf Linke, Rafael Rosell, Jesus Corral, Maria Rita Migliorino, Adam Pluzanski, Eric I Sbar, Tao Wang, Jane Liang White, Sashi Nadanaciva, Rickard Sandin, Tony S Mok
BACKGROUND: Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC). METHODS: In this international, multicentre, randomised, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centres and university hospitals in seven countries or special administrative regions...
September 25, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28957405/clinical-characteristics-and-survival-of-lung-cancer-patients-associated-with-multiple-primary-malignancies
#10
Shan Shan, Jun She, Zhi-Qiang Xue, Chun-Xia Su, Shen-Xiang Ren, Feng-Ying Wu
OBJECTIVES: To investigate the characteristics and survival of lung cancer patients with additional malignant primary cancers. METHODS: Records of lung cancer patients newly diagnosed in Shanghai Pulmonary Hospital between January 2000 and January 2010 were retrospectively reviewed. Patients with second primary lung cancer and those with lung cancer only were included for detailed analysis. RESULTS: Of 27642 newly diagnosed lung cancer patients, 283 patients (1...
2017: PloS One
https://www.readbyqxmd.com/read/28955001/aggressive-resection-of-metachronous-triple-biliary-cancer
#11
Masato Yoshikawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saito, Shinichiro Yamada, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto, Mitsuo Shimada
Radical resection of recurrent cholangiocellular carcinoma (CCC) is rare. To date, only two patients have been reported to undergo major hepatectomy twice after pancreatoduodenectomy (PD) for metachronous CCC. This report describes a patient who underwent three metachronous radical resections of CCC with curative intent, consisting of PD followed by two hepatectomies, for cancer of the middle bile duct. A 60 year old male, who had undergone a distal gastrectomy for duodenal ulcer perforation in 23 years ago, underwent PD (Honjo method) for middle bile duct cancer (papillary adenocarcinoma) in 20 years ago at another hospital...
2017: Journal of Medical Investigation: JMI
https://www.readbyqxmd.com/read/28945850/first-line-icotinib-versus-cisplatin-pemetrexed-plus-pemetrexed-maintenance-therapy-for-patients-with-advanced-egfr-mutation-positive-lung-adenocarcinoma-convince-a-phase-3-open-label-randomized-study
#12
Y K Shi, L Wang, B H Han, W Li, P Yu, Y P Liu, C M Ding, X Song, Z Y Ma, X L Ren, J F Feng, H L Zhang, G Y Chen, X H Han, N Wu, C Yao, Y Song, S C Zhang, W Song, X Q Liu, S J Zhao, Y C Lin, X Q Ye, K Li, Y Q Shu, L M Ding, F L Tan, Y Sun
Background: Icotinib has been previously shown to be non-inferior to gefitinib in non-selected advanced non-small-cell lung cancer patients when given as second- or further-line treatment. In this open-label, randomized, phase 3 CONVINCE trial, we assessed the efficacy and safety of first-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutation. Patients and methods: Eligible participants were adults with stage IIIB/IV lung adenocarcinoma and exon 19/21 EGFR mutations...
October 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28943681/robust-treatment-comparison-based-on-utilities-of-semi-competing-risks-in-non-small-cell-lung-cancer
#13
Thomas A Murray, Peter F Thall, Ying Yuan, Sarah McAvoy, Daniel R Gomez
A design is presented for a randomized clinical trial comparing two second-line treatments, chemotherapy versus chemotherapy plus reirradiation, for treatment of recurrent non-small-cell lung cancer. The central research question is whether the potential efficacy benefit that adding reirradiation to chemotherapy may provide justifies its potential for increasing the risk of toxicity. The design uses two co-primary outcomes: time to disease progression or death, and time to severe toxicity. Because patients may be given an active third-line treatment at disease progression that confounds second-line treatment effects on toxicity and survival following disease progression, for the purpose of this comparative study follow-up ends at disease progression or death...
2017: Journal of the American Statistical Association
https://www.readbyqxmd.com/read/28937324/impact-of-2-staged-stereotactic-radiosurgery-for-treatment-of-brain-metastases-%C3%A2-2-cm
#14
Lilyana Angelov, Alireza M Mohammadi, Elizabeth E Bennett, Mahmoud Abbassy, Paul Elson, Samuel T Chao, Joshua S Montgomery, Ghaith Habboub, Michael A Vogelbaum, John H Suh, Erin S Murphy, Manmeet S Ahluwalia, Sean J Nagel, Gene H Barnett
OBJECTIVE Stereotactic radiosurgery (SRS) is the primary modality for treating brain metastases. However, effective radiosurgical control of brain metastases ≥ 2 cm in maximum diameter remains challenging and is associated with suboptimal local control (LC) rates of 37%-62% and an increased risk of treatment-related toxicity. To enhance LC while limiting adverse effects (AEs) of radiation in these patients, a dose-dense treatment regimen using 2-staged SRS (2-SSRS) was used. The objective of this study was to evaluate the efficacy and toxicity of this treatment strategy...
September 22, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28932562/standardized-uptake-value-and-radiological-density-attenuation-as-predictive-and-prognostic-factors-in-patients-with-solitary-pulmonary-nodules-our-experience-on-1-592-patients
#15
Duilio Divisi, Mirko Barone, Luca Bertolaccini, Gaetano Rocco, Piergiorgio Solli, Roberto Crisci
BACKGROUND: Multislice computed tomography (MSCT) increased detection of solitary pulmonary nodules (SPNs), changing the management based on radiological and clinical factors. When 18-fluorine fluorodeoxyglucose positron emission tomography combined with computed tomography ((18)F-FDG-PET/CT) was considered for the evaluation of nodules, the maximum standardized uptake value (SUVmax) more than 2.5 is used frequently as a cut off for malignancy. The purpose of this study is to evaluate SUVmax PET/CT and pulmonary attenuation patterns at MSCT in patients with SPN according to morphological and pathological characteristics of the lesion...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28927134/primary-mucinous-adenocarcinoma-of-the-lung-a-case-report-and-review-of-the-literature
#16
Yan Liu, He-Long Zhang, Jia-Zhuan Mei, Yan-Wei Guo, Rui-Jun Li, Si-Dong Wei, Fu Tian, Lu Yang, Hui Wang
Mucinous adenocarcinoma is an unusual histological type of lung cancer, and its clinicopathological feature is distinctive from that of other histopathological types of lung adenocarcinoma. Mucinous adenocarcinoma has a mucus-producing function, which explains its name. The present study reports a rare case of a mucus-producing adenocarcinoma of the lung. A 60-year-old Chinese female patient was diagnosed with mucinous adenocarcinoma of the lung, which manifested as respiratory symptoms, including fever, cough and expectoration...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28919394/concomitant-chemotherapy-and-radiotherapy-with-sbrt-boost-for-unresectable-stage-iii-non-small-cell-lung-cancer-a-phase-i-study
#17
Kristin A Higgins, Rathi N Pillai, Zhengjia Chen, Sibo Tian, Chao Zhang, Pretesh Patel, Suchita Pakkala, Jay Shelton, Seth D Force, Felix G Fernandez, Conor E Steuer, Taofeek K Owonikoko, Suresh S Ramalingam, Jeffrey D Bradley, Walter J Curran
PURPOSE: Stereotactic Body Radiation Therapy (SBRT) is now the standard of care in medically inoperable stage I non-small cell lung cancer, yielding high rates of local control. It is unknown if SBRT can be safely utilized in the locally advanced NSCLC setting. This multi-institution phase I study evaluated the safety of 44 Gy conventionally fractionated thoracic radiation with concurrent chemotherapy plus a dose escalated SBRT boost to both the primary tumor and involved mediastinal lymph nodes...
September 12, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28867545/never-too-old-a-single-institution-experience-of-stereotactic-body-radiation-therapy-for-patients-90-years-and-older-with-early-stage-lung-cancer
#18
Gregory M M Videtic, Neil M Woody, Chandana A Reddy, Kevin L Stephans
PURPOSE: To report on the patient, tumor, and treatment characteristics of patients aged 90 years or older who were treated with lung stereotactic body radiation therapy (SBRT) for early stage lung cancer and the resulting clinical outcomes. METHODS AND MATERIALS: We surveyed our institutional review board-approved prospective lung SBRT data registry for patients aged 90 years or older who were treated for early stage lung cancer to determine the rates of local failure, progression-free survival, and overall survival as well as treatment-related toxicity...
June 29, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28854914/factors-related-with-colorectal-and-stomach-cancer-screening-practice-among-disease-free-lung-cancer-survivors-in-korea
#19
Sang Min Park, Jongmog Lee, Young Ae Kim, Yoon Jung Chang, Moon Soo Kim, Young Mog Shim, Jae Ill Zo, Young Ho Yun
BACKGROUND: Lung cancer survivors are more likely to develop colorectal and stomach cancer than the general population. However, little is known about the current status of gastrointestinal cancer screening practices and related factors among lung cancer survivors. METHODS: We enrolled 829 disease-free lung cancer survivors ≥40 years of age, who had been treated at two hospitals from 2001 to 2006. The patients completed a questionnaire that included stomach and colorectal cancer screening after lung cancer treatment, as well as other sociodemographic variables...
August 30, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28843176/risk-of-second-primary-cancers-among-patients-with-a-first-primary-gastric-cancer-a-population-based-study-in-north-portugal
#20
Samantha Morais, Luís Antunes, Maria José Bento, Nuno Lunet
BACKGROUND: The growing number of incident cases of gastric cancer along with improved survival result in a rising population of survivors at risk of second primary cancers (SPC). We estimated the cumulative incidence of metachronous (diagnosed >2months after first primary cancer [FPC]) SPC in gastric FPC patients and compared the incidence of metachronous SPC with that expected in the general population. METHODS: A cohort of gastric FPC patients from the North Region Cancer Registry of Portugal, diagnosed in 2000-2006 (n=7427) was followed to 31 December 2010 for synchronous and metachronous SPCs...
August 23, 2017: Cancer Epidemiology
keyword
keyword
89877
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"